Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 30

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Tertiary adrenal insufficiency

Not recruiting

Study on Hydrocortisone and Placebo for Patients with Giant Cell Arteritis or Polymyalgia Rheumatica Experiencing Adrenal Insufficiency Symptoms

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Odense University Hospital

Impaired gastric emptying+1

Not recruiting

Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Naronapride Dihydrochloride Trihydrate
  • Sponsor:Dr. Falk Pharma GmbH

Neuroblastoma

Not recruiting

Study on the Safety of Lutetium (177Lu) Oxodotreotide with Arginine and Lysine in Children with Refractory or Recurrent Neuroblastoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Lysine Hydrochloride
  • Sponsor:Oncopole Claudius Regaud

Phaeochromocytoma

Not recruiting

Study on [18F]mFBG PET-CT Imaging for Patients with Pheochromocytoma

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:M-(18F)-fluorobenzylguanidine
  • Sponsor:Universitair Medisch Centrum Utrecht

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Diabetic retinopathy+1

Not recruiting

Study on the Effectiveness and Safety of BAY 3283142 in Reducing Urine Albumin for Patients with Chronic Kidney Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BAY 3283142
  • Sponsor:Bayer AG

Carcinoid syndrome

Not recruiting

Study on the Safety and Effects of Paltusotine and Octreotide Acetate for Patients with Carcinoid Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Octreotide Acetate
  • Sponsor:Crinetics Pharmaceuticals Inc.

Endocrine ophthalmopathy

Not recruiting

Study of Lu AG22515 for Adults with Moderate-to-Severe Thyroid Eye Disease

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:Human (scFv)2-FAB fusion protein against CD40L
  • Sponsor:H. Lundbeck A/S

Primary adrenal insufficiency

Not recruiting

Study on Quality of Life in Patients Aged 16-80 with Primary Adrenal Insufficiency Using Hydrocortisone (Plenadren) and Cortisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Cortisone
  • Sponsor:Helse Bergen HF

Myotonic dystrophy

Not recruiting

Study on AOC 1001 for Treating Myotonic Dystrophy Type 1 in Patients

Investigational
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Monoclonal Antibody Against Tfr1 Conjugated To Double Stranded Sirna Oligonucleotide Against Dmpk Via A Non-Cleavable Linker
  • Sponsor:Avidity Biosciences Inc.

Wolfram syndrome

Not recruiting

Study on Tirzepatide for Improving Insulin Production in Patients with Wolfram Syndrome Type 1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tirzepatide
  • Sponsor:Ospedale San Raffaele S.r.l.

Neuroblastoma

Not recruiting

Study of LY3295668 Erbumine for Patients with Relapsed or Refractory Neuroblastoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:(2R,4R)-1-(3-Chloro-2-Fluorobenzyl)-4-((3-Fluoro-6-((5-Methyl-1H-Pyrazol-3-Yl)Amino)Pyridin-2-Yl)Methyl)-2-Methylpiperidine-4-Carboxylic Acid
  • Sponsor:Eli Lilly & Co.

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.